Medtronic is upping the ante in patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic's InterStim device, an implanted ...
Medtronic continues to up its game in sacral neuromodulation. FDA approved InterStim X, the next generation of the company's InterStim portfolio's recharge-free device. Medtronic said implants have ...
Stimguard LLC will begin enrollment for a head-to-head study of its Chronic Affarent Nerve Stimulator (CAN-stim) against Medtronic plc's gold standard Interstim device in treatment of urgency urinary ...
DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for ...
Axonics gets a new chance to invalidate two Medtronic nerve-stimulation patents Related Medtronic lawsuit scheduled for trial in August The U.S. Court of Appeals for the Federal Circuit said, opens ...
After receiving an FDA approval last month in bladder and bowel incontinence for its neuromodulation device implanted in the lower back, Medtronic isn’t resting on its laurels. It has begun a clinical ...
DUBLIN, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that its recently FDA-approved InterStim™ Micro neurostimulator for sacral ...
As Medtronic and Axonics’ legal battle over alleged similarities between their sacral neuromodulation devices drags on, Medtronic is getting the U.S. International Trade Commission involved. The ...
Dublin-based Medtronic plc has filed a PMA supplement with the U.S. FDA for its next-generation, implantable sacral neuromodulation (SNM) device, Interstim Micro, and for its Interstim Surescan MRI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback